HEPATOCELLULAR CARCINOMA (HCC)
Clinical trials for HEPATOCELLULAR CARCINOMA (HCC) explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CARCINOMA (HCC) trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CARCINOMA (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cancer drug INCB062079 tested in 25 patients, study halted early
Disease control TerminatedThis early-phase study tested the safety of a new drug, INCB062079, in 25 people with advanced liver cancer or other solid tumors. The goal was to find a safe dose and see how well patients tolerated the treatment. The study was terminated early, so results are limited.
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 06:11 UTC
-
Liver cancer drug trial halted: could cadonilimab stop recurrence?
Disease control TerminatedThis study looked at whether the drug cadonilimab could help prevent liver cancer from returning in patients who had surgery to remove their tumor but were at high risk of recurrence. The trial planned to enroll 45 adults aged 18-70 with good performance status. The study was ter…
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated May 19, 2026 12:00 UTC